The board of bladder cancer diagnostics company Pacific Edge will spend the next day and a half “in a room” planning a response to a looming US decision affecting sales, shareholders heard at its annual meeting yesterday.
The much-delayed decision on whether Pacific Edge’s Cxbladder product
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
